Celcuity Stock
Celcuity Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brian F. Sullivan
- Employees
- 155
- Market cap
- $2.8 B
- IPO
- 19/09/2017
Celcuity Inc. is a healthcare company operating in the biotechnology sector, headquartered in Minneapolis, US. The company operates as a cellular analysis firm focused on discovering new cancer subtypes and commercializing diagnostic tests designed to improve clinical outcomes for cancer patients treated with targeted…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Celcuity stock: price history
1D
-6.2%
1W
-16.7%
1M
-31.5%
6M
-53.8%
YTD
-43.3%
1Y
+7.7%
2Y
+255.8%
5Y
+210.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~13% weaker price swings than usual
Ask the agents about Celcuity
Analyst assessment of Celcuity
PRICE TARGET LOW
US$140.00
CONSENSUS
US$159.88
MEDIAN
US$157.50
PRICE TARGET HIGH
US$178.00
0
STRONG BUY
12
BUY
0
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 30/09/2026
Celcuity stock metrics
P/E
-13.19
P/B
-242.67
EV/EBITDA
-18.04
RETURN ON EQUITY
617.0%
NET MARGIN
0.0%
DEBT/EQUITY
-59.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.7%
FLOAT SHARES
29,716,837
AVG. DAILY VOLUME (30D)
1,399,367
Insider transactions (SEC)
Furcht Leo
GRYSKA DAVID W
Laing Lance G.
Sullivan Brian F.
Hahne Vicky
Institutional holders
Comparable stocks
Frequently asked questions about Celcuity stock
What does Celcuity do?
Celcuity Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brian F. Sullivan, the company employs around 155 people.
The IPO was on 19/09/2017; the stock trades on NASDAQ under the ticker CELC.
What do analysts say about Celcuity stock?
12 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$159.88, ranging from US$140.00 to US$178.00, with a median of US$157.50.
This is an external assessment, not a statement by Market Jury.
When does Celcuity report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
Does Celcuity pay a dividend?
No, Celcuity currently does not pay a dividend.
Which stocks are comparable to Celcuity?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Celcuity stock analyzed?
Clicking "Analyze stock" lets five strategies assess Celcuity against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.